Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Dihexa | Hexarelin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 10-20 mg daily via oral or sublingual administration. | Research indicates 100-200 mcg administered 1-2 times daily via subcutaneous injection. |
| Timing | Morning dosing preferred. Can be taken with or without food (orally active). | On empty stomach, bedtime preferred. Avoid prolonged continuous use due to rapid desensitization. |
| Cycle Duration | 2-4 week cycles with equal rest periods. Long-term safety data is extremely limited. | 4-8 week cycles maximum, then 4+ week break. Hexarelin desensitizes faster than other GHRPs. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is an orally active, blood-brain barrier-permeable oligopeptide derived from angiotensin IV. It binds hepatocyte growth factor (HGF) with high affinity, inhibiting HGF dimerization and synergistically promoting c-Met receptor phosphorylation and signaling. Activation of HGF/c-Met drives procognitive effects through increased dendritic arborization, spinogenesis, and synaptogenesis via the PI3K/AKT signaling pathway. Research indicates it is approximately 10 million times more potent than BDNF for new synapse formation.
Research indicates 10-20 mg daily via oral or sublingual administration.
Morning dosing preferred. Can be taken with or without food (orally active).
2-4 week cycles with equal rest periods. Long-term safety data is extremely limited.
Hexarelin (Examorelin) is a synthetic hexapeptide GHS-R1a agonist and the most potent synthetic GH secretagogue by peak GH release. It stimulates GH release through both pituitary ghrelin receptors and hypothalamic pathways, with mechanisms involving regulation of GHRH and somatostatin. Hexarelin also demonstrates significant cardiac benefits through activation of cardiac GHS-R1a receptors, protecting against ischemia-reperfusion injury and reducing cardiac fibrosis via the CD36 scavenger receptor pathway.
Research indicates 100-200 mcg administered 1-2 times daily via subcutaneous injection.
On empty stomach, bedtime preferred. Avoid prolonged continuous use due to rapid desensitization.
4-8 week cycles maximum, then 4+ week break. Hexarelin desensitizes faster than other GHRPs.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →